Healthcare
Wesana Health Holdings Inc.(WSNAF)
Live Price
Offline$0.0163
+0.00% today
1Y Change
-35.57%
Window
Jun 20, 2025 → Jun 16, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- +79.1%
- Dividend Yield
- 0.0%
Coverage: 250 bars · Jun 20, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Wesana Health Holdings Inc. (WSNAF) is a Healthcare stock with listed on OTC. The stock last traded around $0.02 and down 35.6% across the available one-year price window (Jun 20, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +79.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +79.1%, free cash flow +88.7% with operating margin 0.0% and ROIC 4706.5%. Stock Foundry combines WSNAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +79.1%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WSNAF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WSNAF Max Drawdown
-90.36%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for WSNAF and SPY.
Company Overview
Wesana Health Holdings Inc.
Other OTC
Wesana Health Holdings Inc, a life sciences company, engages in the development and delivery of psychedelic medicines and psilocybin-assisted psychotherapies to treat traumatic brain injuries. It is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological, and mental health ailments caused by trauma. The company is based in Chicago, Illinois.
- Leadership
- Daniel Carcillo
- IPO Date
- Jun 4, 2021
- Employees
- 7
- Street Address
- 433 W Van Buren Street
- Mailing
- Chicago, IL, 60607
- Region
- Chicago, IL, US
- Reporting Currency
- USD
- Investor Line
- 773 236 7972
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- +79.1%
- Free Cash Flow
- +88.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -506.8%
- ROIC
- 4706.5%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.49
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.